Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present data at PAINWeek 2025 regarding the impact of diabetic peripheral neuropathic pain (DPNP) on patients. The presentation, scheduled for September 4, 2025, will showcase insights from a patient survey related to the development of Pilavapadin.
The study focuses on patients' experiences with DPNP despite using current pain relief options. The presentation highlights that diabetic neuropathy affects nearly 50% of diabetes patients during their lifetime, with 25-30% suffering from DPNP specifically, characterized by burning, tingling, and numbness that significantly impacts quality of life.
Lexicon Pharmaceuticals (NASDAQ:LXRX) presented compelling post-hoc analysis results for sotagliflozin at the ESC 2025 Congress in Madrid. The analysis, pooling data from SCORED and SOLOIST-WHF trials with nearly 12,000 participants, demonstrated consistent cardiovascular benefits across all age groups.
The study showed sotagliflozin, a dual SGLT-1 and SGLT-2 inhibitor, reduced heart failure endpoints and major cardiovascular events regardless of age. Key findings include reduction in cardiovascular death and heart failure hospitalization (8.5 vs 11.8 events/100 person-years) and decreased MACE events (5.7 vs 7.1 events/100 person-years). The drug showed particular efficacy in patients over 65, who represented 70% of the study population.
Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced its participation in two upcoming investor conferences in September 2025. The company will present at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 3:00 p.m. ET.
Both presentations will be available via live webcast and replay through Lexicon's investor relations website at investors.lexpharma.com.
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q2 2025 financial results, highlighting significant progress across its pipeline. The company posted net income of $3.3 million ($0.01 per share) compared to a loss of $53.4 million in Q2 2024, with revenues increasing to $28.9 million from $1.6 million year-over-year.
Key developments include ongoing partnership discussions for pilavapadin following Phase 2b results, progress in IND-enabling studies for LX9851 under a $1 billion potential deal with Novo Nordisk, and advancement of the SONATA Phase 3 study for sotagliflozin in HCM. The company ended Q2 with $139 million in cash and investments plus $29 million in restricted cash.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2). This development ensures LXRX's continued listing on the Nasdaq exchange.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET (7:30 a.m. CT) on the same day.
Management will present the financial results and provide a business update during the call. Investors can access the live webcast through the Events page on Lexicon's investor relations website, and those wishing to ask questions can register to receive dial-in information.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present patient-reported data on diabetic peripheral neuropathic pain (DPNP) at the ASPN 2025 conference in Miami Beach, Florida. The presentation focuses on patient experiences with DPNP, a debilitating chronic complication affecting approximately 9 million patients in the U.S.
The research highlights that DPNP impacts 30% of type 1 diabetes patients and 50% of type 2 diabetes patients, causing symptoms like burning pain and numbness in extremities. The study aims to inform the development of pilavapadin, Lexicon's investigational non-opioid treatment for DPNP, and raise awareness among healthcare professionals about patient burden.
Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its upcoming participation in the 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5 at 12:50 p.m. ET in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.